Financial Contrast: Psyence Biomedical (PBM) versus Its Rivals

Psyence Biomedical (NASDAQ:PBM) is one of 618 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its competitors? We will compare Psyence Biomedical to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, institutional ownership, dividends and earnings.

Risk and Volatility

Psyence Biomedical has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Psyence Biomedical’s competitors have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Psyence Biomedical and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Psyence Biomedical Competitors	-1,429.64%	-640.77%	-28.28%

Valuation and Earnings

This table compares Psyence Biomedical and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Psyence Biomedical	N/A	$1.01 million	0.67
Psyence Biomedical Competitors	$963.48 million	-$44.00 million	14.52

Psyence Biomedical’s competitors have higher revenue, but lower earnings than Psyence Biomedical. Psyence Biomedical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations for Psyence Biomedical and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1	0	0	0	1.00
Psyence Biomedical Competitors	5313	11937	37203	1120	2.61

As a group, “MED – BIOMED/GENE” companies have a potential upside of 67.14%. Given Psyence Biomedical’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Psyence Biomedical has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 51.1% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Psyence Biomedical competitors beat Psyence Biomedical on 8 of the 13 factors compared.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.